• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.25% Nasdaq Up0.65%

    Cytokinetics, Incorporated (CYTK)

    8.11 Up 0.03(0.37%) May 27, 4:00PM EDT
    ProfileGet Profile for:
    Cytokinetics, Incorporated
    280 East Grand Avenue
    South San Francisco, CA 94080
    United States - Map
    Phone: 650-624-3000
    Fax: 650-624-3010
    Website: http://www.cytokinetics.com

    Index Membership:N/A
    Full Time Employees:100

    Business Summary 

    Cytokinetics, Incorporated, a late stage biopharmaceutical company, focuses on the discovery and development of novel small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. It is developing tirasemtiv, a fast skeletal muscle troponin activator that is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis; CK-2127107, which is in Phase II clinical trials for the treatment of spinal muscle atrophy; and omecamtiv mecarbil, a novel cardiac muscle myosin activator that is in Phase II clinical trials for the treatment of heart failure. The company has strategic alliances with Amgen Inc. to discover, develop, and commercialize novel small molecule therapeutics that activate cardiac muscle contractility for applications in the treatment of heart failure; and Astellas Pharma Inc. to advance novel therapies for diseases and medical conditions associated with muscle weakness. Cytokinetics, Incorporated has a research collaboration with Origent Data Sciences to refine and validate a computer model to predict the course of ALS disease progression. The company was founded in 1997 and is headquartered in South San Francisco, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Cytokinetics, Incorporated

    Corporate Governance 
    Cytokinetics, Incorporated’s ISS Governance QuickScore as of May 1, 2016 is 8. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 8; Compensation: 8.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Robert I. Blum , 52
    Chief Exec. Officer, Pres, Director and Chief Exec. of the Biopharmaceutical Concern
    Ms. Sharon A. Surrey-Barbari , 62
    Chief Financial Officer, Exec. VP of Fin. and Corp. Sec.
    Mr. David W. Cragg , 60
    Sr. VP of HR
    Dr. Fady Ibraham Malik M.D., Ph.D., FACC, 52
    Exec. VP of R&D
    Ms. Bonnie A. Charpentier Ph.D., 64
    Sr. VP of Regulatory Affairs & Compliance
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders